INS and type 2 diabetes mellitus: While basal glycogen synthesis was unaffected by roxadustat, insulin-stimulated glycogen synthesis was enhanced by roxadustat pretreatment in myotubes from donors with type 2 diabetes (p=0.0345), to levels observed in myotubes from donors with NGT (Fig. 3c).